未知生产厂商
Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. In some cases, the cells are created from blood samples of patients who have recovered from viral infections.
Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. In some cases, the cells are created from blood samples of patients who have recovered from viral infections.
Administration of VSTs can provide physiological protection against specific infections, especially for patients who are immunocompromised and depleted of T-cells. VSTs are used as an immunotherapy against many infections, including Epstein-Barr virus, adenovirus, BK virus, and human herpesvirus type 6. This type of treatment is also being investigated as a therapy against SARS-Cov-2.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
